Takeda is a large pharma headquartered in Japan. Over the past three years, Takeda has been involved in 30 licensing and acquisition transactions, with a primary focus on Small Molecules (9 deals). The company currently has 50 active clinical trials, primarily in Oncology.
Deals (12mo)
14
Active Trials
50
Top Modality
Small Molecules
Focus Area
Oncology
Licensing, acquisition, and partnership transactions involving Takeda in the past 12 months.
| Asset |
|---|
| Partner |
|---|
| Modality |
|---|
| Phase |
|---|
| Type |
|---|
| Date |
|---|
| olverembatinib | Ascentage | Small Molecules | Unknown | license | May 20, 2026 |
| Gamma delta T-cell platform | GammaDelta Therapeutics | Cell Therapy | Preclinical | option | May 19, 2026 |
| olverembatinib | Ascentage Pharma | Small Molecules | Phase 3 | license | May 15, 2026 |
| rusfertide | Protagonist Therapeutics | Peptides | Unknown | license | Apr 28, 2026 |
| olverembatinib | Ascentage Pharma | Small Molecules | Unknown | license | Apr 15, 2026 |
| Rusfertide | Protagonist | Peptides | Unknown | license | Apr 15, 2026 |
| DLL3 | Caribou Biosciences | mRNA | Phase 1 | acquisition | Dec 16, 2025 |
| LAG-3-301 | PMV Pharmaceuticals | ADC | Phase 2 | acquisition | Dec 1, 2025 |
| B7-H3-101 | Karyopharm Therapeutics | Mab | Phase 3 | license | Oct 14, 2025 |
| Claudin 6 | Argenx | Small Molecules | Phase 1 | collaboration | Sep 27, 2025 |
Showing 10 of 12 recent transactions. Upgrade to Pro for full deal history with financials.
Therapeutic areas and modalities where Takeda is most active based on deal history and clinical trial data.
Key indicators of Takeda's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
Takeda has 50 active clinical trials across 6 development phases.
16
Unknown
1
Not Applicable
1
Phase 4
2
Phase 1
12
Phase 2
18
Phase 3
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Takeda is a large pharma company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 30 deals over the past three years, Takeda ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Takeda include Oncology (22 deals and trials), Autoimmune (15 deals and trials), Mega Deals (12 deals and trials), and CNS Disorders (6 deals and trials). In terms of modality, Takeda has shown particular interest in small molecules, peptides, rnai.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Takeda and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Takeda's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,900+ real biopharma licensing deals